Physician profile
Peter B Schrier
NPI 1437390515
$6,274.12
in general payments reported to CMS, 2019-2025
27 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $152 · 2021: $406 · 2022: $756 · 2023: $911 · 2024: $1,023 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,497 · Education: $22.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,496.68 |
| Education | $22.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $565.95 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $557.63 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $549.46 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $524.08 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $440.86 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $399.69 | 2019-2025 | Velphoro, Velphoro |
| Vantive US Healthcare LLC | $362.18 | 2025 | Renal - Pd |
| Akebia Therapeutics INC | $338.10 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $309.20 | 2021-2025 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $288.29 | 2021-2025 | Gattex |
| Novartis Pharmaceuticals Corporation | $257.68 | 2023-2025 | |
| Ardelyx, INC. | $247.79 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $245.13 | 2019 | |
| Glaxosmithkline, LLC. | $205.35 | 2022-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $171.98 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $156.15 | 2019 | |
| Baxter Healthcare | $118.78 | 2023 | Renal - Pd |
| Opko Pharmaceuticals, LLC | $109.52 | 2023-2025 | Rayaldee |
| Nxstage Medical, INC. | $108.94 | 2024-2025 | Nxstage Cartridge Express, Pureflow Sl, Nxstage System One |
| Calliditas Therapeutics US INC. | $67.41 | 2024-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $65.57 | 2023 | Krystexxa |
| Mozarc Medical US LLC | $50.00 | 2025 | Argyle |
| Fresenius USA Manufacturing, INC. | $45.14 | 2025 | |
| Mallinckrodt Hospital Products INC. | $39.81 | 2022 | |
| Renalytix Ai, INC. | $22.01 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Schrier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.